We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Accelerate Diagnostics Inc (AXDX) USD0.001

Sell:$1.10 Buy:$1.42 Change: $0.01 (0.75%)
Market closed |  Prices as at close on 14 June 2024 | Switch to live prices |
Change: $0.01 (0.75%)
Market closed |  Prices as at close on 14 June 2024 | Switch to live prices |
Change: $0.01 (0.75%)
Market closed |  Prices as at close on 14 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.

Contact details

SUITE 108, 303 E 17TH AVE
United States
+1 (303) 8638088

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$28.00 million
Shares in issue:
22.05 million
Health Care Equipment
United States
US dollar

Key personnel

  • John Phillips
    President, Chief Executive Officer, Director
  • David Patience
    Chief Financial Officer
  • Lawrence Mertz
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.